A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Conditions

Ovary

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Ages
18 years and older
Gender
Female only

Find out more about who can participate in this trial

Trial with
OncoQuest Inc.
Start Date
03/24/2021
End Date
06/26/2024

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Alessandro Santin, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Sub-Investigators

Last Updated
07/15/2021
Study HIC
#2000028743

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information